|
Federal court of Canada read out a favourable decision on Ranbaxy's case against Pfizer. Pfizer marketed Atorvastatin,
cholesterol-lowering drug, as Lipitor. The Court invalidated Pfizer's atorvastatin patent CA 2,021,546 as the data provided didn't back up the suggestion of ten-fold increase in activity. On marketing approval, this decision will allow Ranbaxy's generic atorvastatin to enter the Canadian market.
|
